[Cavinton Comforte in the correction of vascular cognitive disorders]. / Kavinton komforte v korrektsii kognitivnykh narushenii pri khronicheskoi ishemii golovnogo mozga.

AIM: To study the effect of cavinton comforte (CC) on the severity of cognitive impairment and motor awkwardness in patients with chronic brain ischemia (HIGM). MATERIAL AND METHODS: There were 30 patients (8 men, 22 women) aged 50-65 years (61.6±4.9 years on average) with AHU with cognitive impairment. We used tests of MINI-Cog, Munsterberg, TMT), ADL). QC appointed 10 mg 3 times a day for 3 months. RESULTS: Against the background of therapy, the improvement of constructive praxis and short-term memory, an increase in the speed of visual search and visual-motor function, an increase in the level of selectivity of attention, an improvement in the reproduction of visual images and perception, an increase in the speed of the motor task (drawing strokes). CONCLUSION: The obtained data can testify about the improvement of indicators of function of a small motility of brushes on the background of improvement of cognitive functions.

[Age dynamics of cognitive functions in persons 50-85 years].

The paper presents original study results of cognitive changes associated with aging in the absence of neurodegenerative, vascular and other significant for cognition disorders in period from 50 to 85 years. It was shown that aging is associated with moderate memory decrease predominantly because of retrieval deficit but not acquisition insufficiency. It was also shown that aging is associated with non-severe executive dysfunction (lack of planning and control). According usual neuropsychological approaches pattern of cognitive changes described above reflects anterior cortical dysfunction or/and impaired interaction between frontal lobes and subcortical basal ganglia. Shows what physiological changes occur with age in the field of memory and executive functions, which is of great clinical importance for the differential diagnosis of normal aging and early stages of common in the elderly cerebral diseases.

[Neuromidin in mixed vascular and Alzheimer's dementia].

The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer's dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug. The positive effect was seen in 53,3% of patients of the main group. The worsening was observed in 40% of patients of the comparison group. The positive effect of the drug on spatial and neurodynamic functions was revealed. No serious side-effects of the treatment were found.

[Tanakan (EGb 761) in the therapy of mild cognitive impairment].

Mild Cognitive Impairment (MCI) means cognitive deterioration not yet causing disability or dementia. Aged patients with MCI constitute a group of high risk for Alzheimer disease and other types of dementia. Currently, there is no generally adopted approach to MCI management but medications with neuroprotective properties are presumed to be the most perspective. Presented are the results of a multicentral open-label clinical trial of vascular and neuroprotective drug tanakan (EGb 761). The study has shown the decrease of cognitive impairment, which was both clinically and statistically significant, in patients at early stages of vascular and neurodegenerative pathological process. Probable efficacy of long-term tanakan treatment in prevention of dementia is discussed.

[Moderate cognitive impairment syndrome in cerebral vascular insufficiency].

Frequency of clinical and psychological peculiarities of moderate (mild) cognitive impairment (MCI) in cerebral vascular insufficiency (CVI) was studied in 42 patients, mean age 67.7 +/- 7.7 years. Along with neurological examination, a battery of psychiatric and neuropsychological scales and tests was used. MCI was diagnosed in 28 (66.7%) patients. In 20 patients (47.6%), cognitive hypoactivity was most prominent related to impaired neurodynamics and regulation of voluntary activity which may reflect subcortical and frontal lobes functions. In 8 patients (20.1%), there was a prominent memory impairment characteristic of hippocampus lesion. The authors suggest the presence of concomitant neurodegeneration in patients with amnesic MCI.